Connect Biopharma is trading 7.3% down at $0.74 on October 22, 2026, with no clear cause identified. - The latest identified company news was positive preliminary COPD trial data announced September 30; it does not clearly explain the decline. - Markets were lower amid geopolitical tensions and rising oil. Bloomberg reported caution toward biotechnology stocks as rising Treasury yields weighed on the sector. - Available evidence does not establish a direct cause for this individual move.